183 related articles for article (PubMed ID: 17085445)
1. Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins.
Metz S; Wiesinger M; Vogt M; Lauks H; Schmalzing G; Heinrich PC; Müller-Newen G
J Biol Chem; 2007 Jan; 282(2):1238-48. PubMed ID: 17085445
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptors.
Metz S; Naeth G; Heinrich PC; Müller-Newen G
J Biol Chem; 2008 Mar; 283(10):5985-95. PubMed ID: 18174171
[TBL] [Abstract][Full Text] [Related]
3. A fusion protein of the gp130 and interleukin-6Ralpha ligand-binding domains acts as a potent interleukin-6 inhibitor.
Ancey C; Küster A; Haan S; Herrmann A; Heinrich PC; Müller-Newen G
J Biol Chem; 2003 May; 278(19):16968-72. PubMed ID: 12646580
[TBL] [Abstract][Full Text] [Related]
4. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
5. A receptor fusion protein for the inhibition of murine oncostatin M.
Brolund L; Küster A; Korr S; Vogt M; Müller-Newen G
BMC Biotechnol; 2011 Jan; 11():3. PubMed ID: 21223559
[TBL] [Abstract][Full Text] [Related]
6. Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention.
Veverka V; Baker T; Redpath NT; Carrington B; Muskett FW; Taylor RJ; Lawson AD; Henry AJ; Carr MD
J Biol Chem; 2012 Nov; 287(47):40043-50. PubMed ID: 23027872
[TBL] [Abstract][Full Text] [Related]
7. Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells.
Giese B; Roderburg C; Sommerauer M; Wortmann SB; Metz S; Heinrich PC; Müller-Newen G
J Cell Sci; 2005 Nov; 118(Pt 21):5129-40. PubMed ID: 16254248
[TBL] [Abstract][Full Text] [Related]
8. Formation of autocrine loops in human cerebral meningioma tissue by leukemia inhibitor factor, interleukin-6, and oncostatin M: inhibition of meningioma cell growth in vitro by recombinant oncostatin M.
Schrell UM; Koch HU; Marschalek R; Schrauzer T; Anders M; Adams E; Fahlbusch R
J Neurosurg; 1998 Mar; 88(3):541-8. PubMed ID: 9488310
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
10. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
[TBL] [Abstract][Full Text] [Related]
11. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor.
Skiniotis G; Boulanger MJ; Garcia KC; Walz T
Nat Struct Mol Biol; 2005 Jun; 12(6):545-51. PubMed ID: 15895091
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery.
Görtz D; Braun GS; Maruta Y; Djudjaj S; van Roeyen CR; Martin IV; Küster A; Schmitz-Van de Leur H; Scheller J; Ostendorf T; Floege J; Müller-Newen G
Sci Rep; 2015 Oct; 5():14685. PubMed ID: 26423228
[TBL] [Abstract][Full Text] [Related]
13. In vitro reconstitution of recognition and activation complexes between interleukin-6 and gp130.
Chow D; Ho J; Nguyen Pham TL; Rose-John S; Garcia KC
Biochemistry; 2001 Jun; 40(25):7593-603. PubMed ID: 11412113
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
15. Modular organization of Interleukin-6 and Interleukin-11 α-receptors.
Nitz R; Lokau J; Aparicio-Siegmund S; Scheller J; Garbers C
Biochimie; 2015 Dec; 119():175-82. PubMed ID: 26551279
[TBL] [Abstract][Full Text] [Related]
16. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.
Adam N; Rabe B; Suthaus J; Grötzinger J; Rose-John S; Scheller J
J Virol; 2009 May; 83(10):5117-26. PubMed ID: 19264784
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα/gp130 hexameric signaling complex formation.
Chou CC; Hua KT; Chen MW; Wu CJ; Hsu CH; Wang JT; Hsiao M; Wei LH
MAbs; 2022; 14(1):2029675. PubMed ID: 35133941
[TBL] [Abstract][Full Text] [Related]
18. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
J Clin Invest; 1995 Sep; 96(3):1319-27. PubMed ID: 7657807
[TBL] [Abstract][Full Text] [Related]
19. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
Montero-Julian FA; Brailly H; Sautès C; Joyeux I; Dorval T; Mosseri V; Yasukawa K; Wijdenes J; Adler A; Gorin I; Fridman WH; Tartour E
Clin Cancer Res; 1997 Aug; 3(8):1443-51. PubMed ID: 9815830
[TBL] [Abstract][Full Text] [Related]
20. A new type of cytokine receptor antagonist directly targeting gp130.
Renné C; Kallen KJ; Müllberg J; Jostock T; Grötzinger J; Rose-John S
J Biol Chem; 1998 Oct; 273(42):27213-9. PubMed ID: 9765242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
